AngioDynamics posted second-quarter earnings on Friday, Jan. 4. before trading hours. Net sales for the period inched 5.5% to $91.5 million, with diluted net profit jumping to $0.06 per share — growing six-fold from last year’s $0.01 per share. Net income soared to $2.14 million, up from $249,000.
The market expected earnings of $0.20 per share on revenue of $88.90 million. Both top line and bottom line exceeded the consensus.
Gross margin for the quarter soared 440 basis points year over year to 53.7%, while cash provided by operations was $13.0 million. Capital expenditures was $0.7 million for the period.
US net sales in the quarter rose 5.2% to $71.9 million while International net sales grow 6.6% to $19.6 million.
Back in September, AngioDynamics announced that it would acquire privately held medical diagnostic and device company RadiaDyne. The latter designs and develops patient dose monitoring technology to improve cancer treatment outcomes.
This deal added to AngioDynamics’ portfolio RadiaDyne’s early-stage, proprietary real-time radiation dose monitoring platform and other market-leading oncology solutions.
“The acquisition of RadiaDyne, combined with our recent BioSentry asset purchase, delivers on our commitment to build a world-class oncology portfolio,” said CEO Jim Clemmer.
In September of 2018, RadiaDyne’s trailing 12-months revenues exceeded $6 million. The acquisition was then expected to be neutral to earnings on an adjusted basis.
In the previously reported first-quarter, AngioDynamics missed analyst estimates with earnings of $0.16 per share, sending shares down then. The company had reported flat revenues of $85.3 million over last year, hurt by 6% slump in oncology product sales. it also had a one-time impact in the quarter due to its transition from Acculis to Solero product line.
AngioDynamics has been seeing US sales dipping in the past two quarters, despite international sales picking up. Last quarter, it even had to pay $12.7 million due to the legal allegations faced with the Justice Department.
Biogen (NASDAQ: BIIB) reported third-quarter 2021 financial results before the regular market hours on Wednesday. The company reported Q3 revenue of $2.78 billion, down 18% year-over-year and higher than the
Verizon (NYSE: VZ) reported Third-quarter 2021 financial results before the regular trading hours on Wednesday. The telecommunications giant reported Q3 revenue of $32.9 billion, up 4.3% year-over-year and above the
Philip Morris International Inc. (NYSE: PM) reported Third-quarter 2021 earnings results today. Net revenues increased 9% year-over-year to $8.1 billion. The reported net income amounted to $2.42 billion compared to